Skip to main content

Table 1 The relationship between serum CA19-9 levels and clinicopathological factors in 120 cases of PDAC treated by surgical resection

From: Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

Characteristics Number (n = 120) CA19-9 (Median, U/mL) P value
Age (years): Median (Range) 60 (35-80)   
 <60 57 (47.5%) 297.20 0.879
 ≥60 63 (52.5%) 243.00  
Gender    
 Male 67 (55.8%) 280.51 0.417
 Female 53 (44.2%) 294.70  
Location of tumor    
 Head 92 (76.7%) 294.95 0.782
 Body or tail 28 (23.3%) 242.30  
Maximal tumor size (cm): Median (Range) 4.0 (1.2-10)   
 <4.0 48 (40.0%) 227.65 0.193
 ≥4.0 72 (60.0%) 301.05  
Differentiation    
 well 41 (34.2%) 130.40 0.024
 moderately 68 (56.7%) 467.00  
 poorly 11 (9.1%) 208.77  
Surgical margins    
 Negative 114 (95.0%) 295.95 0.087
 Positive 6 (5.0%) 109.23  
pT category    
 pT1 + pT2 58 (48.3%) 205.10 0.055
 pT3 + pT4 62 (51.7%) 328.60  
pN category    
 pN0 81 (67.5%) 250.00 0.403
 pN1 39 (32.5%) 328.80  
pTNM category    
 I 44 (36.7%) 205.10 0.161
 II 53 (44.2%) 304.90  
 III 23 (19.1%) 558.80  
Serum total bilirubin (μmol/L): Median (Range) 29.80 (2.80-507.30)   
 <34.2 μmol/L (2.0 mg/dL) 63 (52.5%) 187.90 0.025
 ≥34.2 μmol/L (2.0 mg/dL) 57 (47.5%) 332.80